Development of radiolabeled humanized monoclonal antibodies for therapy using gene technology.

本研究项目是通过基因技术开发的放射性人性化单克隆抗体进行实验的，单克隆抗体预计将绑定到肿瘤表达相应的抗体上。由于这种目的，Murano单克隆抗体被用于诊断成像和癌症的治疗。不管怎样，抗生素是从老鼠可能导致过敏反应中衍生出来的，当管理员到病人身上时，应该对物种有所不同。在进行降解的过程中，Murine单克隆抗体的免疫生成性，而Humanized抗体是通过使用基因技术生产的。在目前的研究中，D1131-D1 I-标记的Murine单克隆抗体与CD 20 B细胞抗原在动物体内被调查并确认可在移植肿瘤中累积。After getting the permission from the Ethical committee of our institute D1131--标记抗体against CD 20抗体被安全地管理为患者与非霍奇金淋巴瘤。进一步的研究还有待调查，D1131-标记为A33的单克隆抗体被人类化和管理为胃癌患者（共同调查员Junichi Sakamoto，M.D.）。Aichi Prefectural Hospital和Hiroyuki Kuwano，医学博士。在古马大学医院。这种抗体被收集到与肿瘤到2的血液比率和肿瘤到正常疾病比率之间的抗体。对于各种疾病的治疗，新的放射性细胞被调查成类似于rhenium-186和yttrium-90的抗体，如果希望有适合临床使用的特征。

This research project was performed to investigate the radiolabeled humanized monoclonal antibodies developed by gene technology.Monoclonal antibodies are expected to bind to the tumor expressing the corresponding antigens. For this purpose murine monoclonal antibodies are used for the diagnostic imagings and the therapy of cancers. However, antibodies derived from mice may cause allergic reactions, when administered to patients, due to the species difference. In order to decrease the immunogenecity of murine monoclonal antibodies, humanized antibodies are produced by using the gene technology. In the present study, ィイD1131ィエD1I-labeled murine monoclonal antibodies reactive with CD20 B cell antigen were investigated in the animals and confirmed to accumulate in the transplanted tumor. After getting the permission from the ethical committee of our institute ィイD1131ィエD1I-labeled antibody against CD20 antigen was safely administered to patients with non-Hodgkin lymphoma. Further studies remains to be in vestigated.ィイD1131ィエD1I-labeled monoclonal antibody named A33 was humanized and administered to gastric cancer patients (Co-investigator Junichi Sakamoto, M.D. of Aichi Prefectural Hospital and Hiroyuki Kuwano, M.D. of Gunma University Hospital). This antibody accumulated to cancer tissue with tumor to blood ratios of about 2 and tumor to normal tissue ratio of about 4.For the therapy of various diseases, new radionuclides have been investigated such as rhenium-186 and yttrium-90, which are expected to have favorable characteristics for clinical use.